Literature DB >> 11161629

Distinct inflammatory stimuli induce different patterns of myelin phagocytosis and degradation in recruited macrophages.

U Slobodov1, F Reichert, R Mirski, S Rotshenker.   

Abstract

Injury and demyelinating diseases result in the disruption of the myelin sheath that surrounds axons in the nervous system. The removal of degenerating myelin by macrophages and microglia is central to repair mechanisms that follow. The efficiency of myelin removal depends on magnitudes and rates of myelin phagocytosis and degradation. In the present study we test whether environmental conditions within a tissue can control patterns of myelin removal. We document that macrophages that are recruited to the same tissue but by distinct inflammatory stimuli differ in their ability to phagocytose and degrade myelin. These observations may apply to the nervous system where different pathological conditions that involve distinct inflammatory stimuli may induce different functional states in microglia and macrophages. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161629     DOI: 10.1006/exnr.2000.7559

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  16 in total

Review 1.  Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain.

Authors:  Burkhard Becher; Ingo Bechmann; Melanie Greter
Journal:  J Mol Med (Berl)       Date:  2006-06-14       Impact factor: 4.599

2.  Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury.

Authors:  Kristina A Kigerl; Violeta M McGaughy; Phillip G Popovich
Journal:  J Comp Neurol       Date:  2006-02-01       Impact factor: 3.215

Review 3.  Myelin as an inflammatory mediator: Myelin interactions with complement, macrophages, and microglia in spinal cord injury.

Authors:  Timothy J Kopper; John C Gensel
Journal:  J Neurosci Res       Date:  2017-07-11       Impact factor: 4.164

4.  The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta.

Authors:  Shlomit Shamash; Fanny Reichert; Shlomo Rotshenker
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

Review 5.  Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease.

Authors:  Shlomo Rotshenker
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

6.  CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages.

Authors:  Corinna Trebst; Susan M Staugaitis; Pia Kivisäkk; Don Mahad; Martha K Cathcart; Barbara Tucky; Tao Wei; Mysore R Sandhya Rani; Richard Horuk; Kenneth D Aldape; Carlos A Pardo; Claudia F Lucchinetti; Hans Lassmann; Richard M Ransohoff
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 7.  The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease.

Authors:  Shlomo Rotshenker
Journal:  J Mol Neurosci       Date:  2009-02-28       Impact factor: 3.444

8.  Complement receptor-3 negatively regulates the phagocytosis of degenerated myelin through tyrosine kinase Syk and cofilin.

Authors:  Smadar Hadas; Maya Spira; Uwe-Karsten Hanisch; Fanny Reichert; Shlomo Rotshenker
Journal:  J Neuroinflammation       Date:  2012-07-09       Impact factor: 8.322

9.  Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα (signal regulatory protein-α) on phagocytes.

Authors:  Miri Gitik; Sigal Liraz-Zaltsman; Per-Arne Oldenborg; Fanny Reichert; Shlomo Rotshenker
Journal:  J Neuroinflammation       Date:  2011-03-15       Impact factor: 8.322

10.  Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor.

Authors:  Yasuyuki Kihara; Satoshi Ishii; Yoshihiro Kita; Akiko Toda; Atsuyoshi Shimada; Takao Shimizu
Journal:  J Exp Med       Date:  2005-09-19       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.